RxDoctor Payments Data

William McDonough, MD

Family Medicine · The Woodlands, TXNPI 1124647573

Payments from drug & device makers

$2,782in general payments, 2019–2025

Across 128 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$446
  • GSK$426
  • AstraZeneca$331
  • Novo Nordisk$297
  • AbbVie$269
  • Pfizer$266
  • plus $748 from 10 others

What the payments were for

  • Food & beverage$2,782100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,782 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$105,612
Medicare patients
319
Services billed
2,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide48$50,318
FarxigaDapagliflozin Propanediol26$30,997
TrulicityDulaglutide24$23,495
OzempicSemaglutide21$22,568
JardianceEmpagliflozin11$12,896
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,252
Metformin Hcl ErMetformin Hcl58$1,136
Levothyroxine Sodium98$1,087
Celecoxib15$917
Gabapentin60$898
Atorvastatin Calcium79$846
Rosuvastatin Calcium65$829
Fenofibrate11$751
Losartan Potassium65$749
Pregabalin24$673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$446$73,81372 claims
AstraZenecaFarxiga$331$30,99726 claims
Novo NordiskOzempic$297$22,56821 claims
Boehringer IngelheimJardiance$209$12,89611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →